Suppr超能文献

肿瘤特异性抑制性T细胞,其可抑制从免疫宿主和早期荷瘤宿主脾脏中体外产生细胞毒性T细胞。

Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.

作者信息

Bear H D

出版信息

Cancer Res. 1986 Apr;46(4 Pt 1):1805-12.

PMID:2936451
Abstract

Spleen cells from DBA/2 mice, after immunization with syngeneic P815 mastocytoma cells and Corynebacterium parvum, respond to P815 in vitro with a brisk, secondary-type generation of cytotoxic cells. This cytotoxicity is mediated by antigen-specific T-lymphocytes and correlates with resistance to in vivo challenge. This model confirms the observations of previous investigators made in semisyngeneic hosts using an in vivo transfer model. Spleen cells from "early" tumor-bearing hosts (TBHs), 7-12 days after intradermal (i.d.) inoculation of 10(6) P815 cells alone, made a similar, but generally higher, cytotoxic T-lymphocyte (CTL) response in vitro. Spleen cells from "late" TBHs (18-28 days) completely suppressed the in vitro CTL response of immune cells (e.g., from 71% specific release in controls down to 8% at an effector: target ratio of 40:1). Early i.d. TBH spleen cells, because of their higher level response, appeared to be resistant to this suppression (85% release for controls and 84% when suppressor cells were added at 40:1). By testing early TBH CTL at lower effector: target ratios, however, suppression by late TBH spleen cells could be readily demonstrated. When TBHs were inoculated s.c. instead of i.d. or with lower doses of tumor cells, responses were lower and susceptibility of splenic CTLs to suppression was increased. At intermediate times after tumor inoculation (14-20 days), spleen cells from TBHs still can respond in vitro, but they are completely suppressed by spleen cells from late TBHs. The suppressor cells are antigen-specific, radiation-sensitive, Thy1+ cells.

摘要

用同基因P815肥大细胞瘤细胞和短小棒状杆菌免疫后的DBA/2小鼠脾细胞,在体外对P815产生快速的、继发性细胞毒性细胞生成反应。这种细胞毒性由抗原特异性T淋巴细胞介导,并与体内攻击抗性相关。该模型证实了先前研究者在半同基因宿主中使用体内转移模型所做的观察。在皮内接种10(6)个P815细胞后7 - 12天的“早期”荷瘤宿主(TBH)的脾细胞,在体外产生了类似但通常更高的细胞毒性T淋巴细胞(CTL)反应。“晚期”TBH(18 - 28天)的脾细胞完全抑制了免疫细胞的体外CTL反应(例如,在效应细胞:靶细胞比例为40:1时,对照中的特异性释放率从71%降至8%)。早期皮内接种TBH的脾细胞由于其较高水平的反应,似乎对这种抑制具有抗性(对照为85%释放,加入抑制细胞时为84%,效应细胞:靶细胞比例为40:1)。然而,通过在较低效应细胞:靶细胞比例下测试早期TBH的CTL,可以很容易地证明晚期TBH脾细胞的抑制作用。当TBH通过皮下而非皮内接种或接种较低剂量的肿瘤细胞时,反应较低,脾CTL对抑制的敏感性增加。在肿瘤接种后的中间时间(14 - 20天),TBH的脾细胞在体外仍能反应,但它们被晚期TBH的脾细胞完全抑制。抑制细胞是抗原特异性的、辐射敏感的、Thy1 +细胞。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验